☆ 4.5 Article

Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia

VACCINE (2011)

期刊

VACCINE

卷 29, 期 16, 页码 3061-3066

出版社

ELSEVIER SCI LTD

DOI: 10.1016/j.vaccine.2011.01.088

关键词

Rotavirus vaccine; Intussusception; Post-marketing surveillance; RotaTeq (R); Rotarix (R); Immunization

类别

Immunology Medicine, Research & Experimental

资金

National Health and Medical Research Council (NHMRC) [402784, 457084]
Department of Health and Ageing, Commonwealth Government of Australia
Sydney Medical School, University of Sydney
CSL Limited
GlaxoSmithKline

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

摘要

Introduction: In Australia, post-marketing surveillance for intussusception following vaccination commenced with funding of RotaTeq (R) and Rotarix (R) vaccines under the National Immunization Program (NIP) in July 2007. Methods: Two active surveillance mechanisms (hospital-based case ascertainment and monthly reports from paediatricians) identified intussusception cases between 1st July 2007 and 31st December 2008 in four states. Linkage to vaccination records identified cases occurring within 1-7 and 1-21 days of rotavirus vaccination. Expected cases within the post-vaccination windows were calculated by applying rates of intussusception from national hospitalisation data over 6 years (mid-2000 to mid-2006), by age and state, to numbers vaccinated (by dose) according to the Australian Childhood Immunization Register. Results: Combining exposure windows associated with all doses of rotavirus vaccine from 1 to 9 months of age, there was no evidence of an increased risk of intussusception following vaccination for either vaccine. However, in infants 1 to <3 months of age, there was suggestive evidence of excess intussusception cases 1-7 and 1-21 days following dose 1(1-7 days: RotaTeq (R) relative risk (RR) = 5.3, 95% confidence interval [Cl] 1.1,15.4; Rotarix (R) RR 3.5,95% Cl 0.7,10.1; 1-21 days: RotaTeq (R) RR 3.5,95% CI 1.3,7.6; Rotarix (R) RR 1.5, 95% CI 0.4, 3.9). There was no evidence that clinical outcome of intussusception occurring within 21 days of rotavirus vaccination differed from that in cases occurring later post-vaccination. Conclusion: Although we found no overall increase in intussusception following receipt of rotavirus vaccine, there was some evidence of an elevated risk following the first dose of both vaccines. Larger population-based studies using linked databases are required to provide more definitive evidence. (C) 2011 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.5

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Evaluation of Intussusception Following Pentavalent Rotavirus Vaccine (RotaTeq) Administration in 5 African Countries

Jacqueline E. Tate, Jason M. Mwenda, Adama Mamby Keita, Toussaint Wendlamita Tapsoba, Edouard Ngendahayo, Bertin Dibi Kouame, Ahmadou Lamin Samateh, Negar Aliabadi, Seydou Sissoko, Yacouba Traore, Justin Bayisenga, Moufidath Sounkere-Soro, Sheriffo Jagne, Rachel M. Burke, Uma Onwuchekwa, Ma Ouattara, Joel B. Bikoroti, Kofi N'Zue, Eyal Leshem, Oumar Coulibaly, Issa Ouedraogo, Jeannine Uwimana, Samba Sow, Umesh D. Parashar

Summary: In a pooled analysis from 5 African countries, RotaTeq vaccination was not associated with an increased risk of intussusception, highlighting the importance of vaccine-specific and setting-specific risk monitoring.

CLINICAL INFECTIOUS DISEASES (2023)